BC003965 Inhibitors
Chemical inhibitors of BC003965 act through various mechanisms to impede its activity by influencing different signaling pathways and cellular processes. Alsterpaullone, as a cyclin-dependent kinase inhibitor, can obstruct the phosphorylation process essential for the activation or stability of BC003965, assuming it is a substrate for these kinases. Concurrently, rapamycin's inhibition of mTOR can lead to a decreased activity of BC003965 if it operates downstream of the mTOR pathway. The PI3K inhibitors LY294002 and Wortmannin are pivotal in diminishing the phosphorylation and subsequent activation of BC003965 by impeding the PI3K/AKT pathway, which is crucial for numerous cellular functions.
In parallel, SB203580 and PD98059, by targeting p38 MAPK and MEK respectively, can suppress the phosphorylation and activation of BC003965 if it is associated with these pathways. U0126, another MEK inhibitor, operates similarly to PD98059 and can restrict the activity of BC003965 through the same mechanism. The JNK inhibitor SP600125 can inhibit the function of BC003965 by preventing its phosphorylation by JNK, assuming BC003965 is a target of this kinase. ZM-447439 and Sotrastaurin target Aurora kinase and protein kinase C (PKC) respectively, and can inhibit BC003965 activity by interfering with these particular kinases responsible for cell cycle progression and other regulatory functions. Bortezomib, by inhibiting the proteasome, can stabilize proteins that inhibit BC003965, thereby reducing its activity indirectly. Lastly, dasatinib, as a broad-spectrum tyrosine kinase inhibitor, can prevent tyrosine kinase-mediated phosphorylation of BC003965, thereby inhibiting its function if it is regulated by such kinases.
SEE ALSO...
Items 1 to 10 of 12 total
Display:
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
Alsterpaullone | 237430-03-4 | sc-202453 sc-202453A | 1 mg 5 mg | $67.00 $306.00 | 2 | |
Alsterpaullone is known to inhibit cyclin-dependent kinases (CDKs). Inhibition of CDKs would prevent the phosphorylation of BC003965, assuming BC003965 requires phosphorylation by CDKs for its activation or stability. | ||||||
Rapamycin | 53123-88-9 | sc-3504 sc-3504A sc-3504B | 1 mg 5 mg 25 mg | $62.00 $155.00 $320.00 | 233 | |
Rapamycin specifically inhibits mTOR (mechanistic target of rapamycin), which is a key regulator of protein synthesis and cell growth. By inhibiting mTOR, the downstream effect would be a reduction in the activity of BC003965, particularly if BC003965 functions downstream of mTOR signaling. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $88.00 $342.00 | 284 | |
SB203580 is a well-characterized inhibitor of p38 MAPK. By inhibiting p38 MAPK, it would interfere with the phosphorylation and activation of proteins that are regulated by this kinase, including BC003965 if it is a downstream target. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $121.00 $392.00 | 148 | |
LY294002 is a PI3K inhibitor, and by inhibiting PI3K, it affects the PI3K/AKT pathway. The inhibition of this pathway would lead to a decrease in the phosphorylation and activation of downstream proteins, potentially including BC003965 if it is part of this signaling axis. | ||||||
Wortmannin | 19545-26-7 | sc-3505 sc-3505A sc-3505B | 1 mg 5 mg 20 mg | $66.00 $219.00 $417.00 | 97 | |
Wortmannin is another PI3K inhibitor that blocks the PI3K/AKT pathway. Its inhibition would reduce the phosphorylation and activation of proteins in the pathway, which would include BC003965 if it is a downstream effector. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $39.00 $90.00 | 212 | |
PD98059 is a MEK inhibitor that would prevent the activation of ERK/MAPK signaling. If BC003965 is activated by the ERK/MAPK pathway, then PD98059 would inhibit its function by blocking this pathway. | ||||||
U-0126 | 109511-58-2 | sc-222395 sc-222395A | 1 mg 5 mg | $63.00 $241.00 | 136 | |
U0126 also inhibits MEK, thereby interfering with the ERK/MAPK signaling cascade. This would inhibit the function of BC003965 if it relies on the ERK/MAPK pathway for its activity. | ||||||
SP600125 | 129-56-6 | sc-200635 sc-200635A | 10 mg 50 mg | $40.00 $150.00 | 257 | |
SP600125 is an inhibitor of JNK (c-Jun N-terminal kinase), which is part of the MAPK family. Inhibition of JNK would suppress the activity of proteins that are phosphorylated and activated by JNK, including BC003965 if it is a JNK substrate. | ||||||
ZM-447439 | 331771-20-1 | sc-200696 sc-200696A | 1 mg 10 mg | $150.00 $349.00 | 15 | |
ZM-447439 is an Aurora kinase inhibitor, which could inhibit cell cycle progression. Should BC003965 be involved in cell cycle regulation through Aurora kinase-dependent mechanisms, this compound would inhibit its function. | ||||||
Sotrastaurin | 425637-18-9 | sc-474229 sc-474229A | 5 mg 10 mg | $300.00 $540.00 | ||
Sotrastaurin is an inhibitor of protein kinase C (PKC). By inhibiting PKC, it would hinder the phosphorylation of proteins that are substrates of PKC, potentially including BC003965 if it is within the PKC signaling pathway. | ||||||